Retatrutide

Retatrutide is an investigational peptide drug being developed for the treatment of obesity and related metabolic disorders. It functions as a triple agonist, targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors.

This multi-receptor agonism aims to enhance glucose metabolism, suppress appetite, and promote weight loss. Retatrutide is intended for individuals with obesity or overweight conditions who may benefit from pharmacological intervention to manage their weight and improve metabolic health.